← All trials
NCT05867472
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2023
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- May 22, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- University of TorontoOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.